• Prostate Cancer Free Home Page
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • News Feed
  • DONATE
Prostate Cancer Free
  • Treatments
    • Treatment Options
    • Compare Treatments
    • – Low Risk
    • – Intermediate Risk
    • – High Risk
    • Side Effects
    • Successful Treatments
    • Get The Study & Booklet
  • Prostate Cancer
    • Prostate Cancer
    • Risk Factors
    • Symptoms
    • The Prostate
    • Tests and Diagnosis
    • PSA
    • Gleason Score
    • Stages
    • Risk Groups
  • Patients
    • Top Ten Steps Prostate Cancer
    • Get the Study & Booklet
    • Patient Worksheet
    • Diet & Lifestyle
    • Glossary & Terms
    • Prostate Cancer News
    • Videos
  • The Foundation
    • About Us
      • Terms of Use
      • Privacy Policy
    • Get the Study & Booklet
    • Study Group
    • Internship Opportunities
    • Sponsors & Donors
    • Donate
  • Get The Study
Select Page

PCa Commentary #181 – PSMA PET/CT Staging of Advanced Prostate Cancer and Artificial Intelligence Guidance in Combining ADT with Radiation.

by Dr. Ed Weber | Sep 28, 2023 | PCa Commentary

Background:  The function of initial staging of prostate cancer is to accurately estimate the risk of progression in order to guide optimal therapy. The influential National Comprehensive Cancer Network (NCCN) recommends a PSMA PET/CT as part of initial staging for...

PCa Commentary # 180 – A Review of a Seminal Study Advancing the Precision of Patient Management

by Dr. Ed Weber | Aug 4, 2023 | PCa Commentary

Background:  Ever since 1675 when the Dutch lens maker, Leeuwenhoek, looked down the newly invented microscope at rainwater and reported seeing ‘animalcules – tiny dancing creatures” (bacteria), pathologists have been similarly looking down their scopes and guiding...

PCa Commentary #179 – NEUROENDOCRINE PROSTATE CANCER: A Challenging Transformation in Late Disease.

by Dr. Ed Weber | Aug 4, 2023 | PCa Commentary

 Background: Although neuroendocrine cancer (NEPC) infrequently (<2%) presents elusively in the prostate,  much more commonly it develops late in the course of disease admixed in varying extent in metastatic lesions with standard adenocarcinoma. In this situation...

PCa Commentary #178 – Radioligand Therapy (RLT): A View into the Future – New Regiments Under Study

by Dr. Ed Weber | Jun 19, 2023 | PCa Commentary

The outcome of the VISION trial, the first reported study of radioligand therapy (RLT) with the radionuclide 177-Lutetium-PSMA-617 targeting the PSMA antigen now serves as the baseline for further development of this promising treatment. The VISION trial studied 831...

PCa Commentary # 177 – DECIPHER: Predicting Prognosis and Assisting Treatment Decisions

by Dr. Ed Weber | May 10, 2023 | PCa Commentary

Decipher assays the RNA expression of 22 genes and estimates the rate of distant metastases at 5 years and prostate cancer-specific mortality at 10 years, thus providing risk stratification to assist in treatment decisions. Three examples: providing guidance for men...
« Older Entries
Prostate Cancer Free Foundation
Prostate Cancer Free Foundation 10016 Edmonds Way Ste C #153 Edmonds, WA 98020, USA [email protected]

Prostate Cancer Treatments

  • Treatment Options
  • Comparing Treatments
    • Low
    • Intermediate
    • High
  • Side Effects
  • Successful Treatments
  • Get the Study & Booklet

Prostate Cancer

  • Prostate Cancer
  • Risk Factors
  • Symptoms
  • The Prostate
  • Tests and Diagnosis
  • PSA
  • Gleason Score
  • Stages
  • Risk Groups

Patients

  • Top Ten Steps Prostate Cancer
  • Get The Study & Booklet
  • Patient Worksheet
  • Diet & Lifestyle
  • Glossary & Terms
  • Commentary & News
  • Videos
Copyright 2021 Prostate Cancer Free Foundation